Warren Davidson Sells Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Font: Financial Modeling Prep  • Mar 26, 2026

• Warren Davidson, a representative from Ohio's 8th district, sold shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) valued between $1,001 and $15,000.
• GE HealthCare is a key player in the healthcare technology sector, focusing on innovative solutions for patient care and actively participating in the COMPASS consortium to enhance precision cardio-oncology care in Europe.
• The company showcases positive growth with a $21.8 billion backlog and a 12.7% increase in the Pharmaceutical Diagnostics segment, despite facing challenges like tariff impacts and margin pressures.

On March 23, 2026, Warren Davidson, a representative from Ohio's 8th district, sold shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC). The transaction was valued between $1,001 and $15,000. GE HealthCare is a prominent player in the healthcare technology sector, focusing on innovative solutions to improve patient care. The company competes with other major healthcare technology firms in delivering advanced medical imaging and diagnostics.

GE HealthCare is actively involved in the COMPASS consortium, a significant initiative aimed at enhancing precision cardio-oncology care in Europe. With a budget of €50.5 million, this five-year project involves over sixty partners and addresses cardiovascular risks in cancer patients. The initiative highlights the growing concern of heart-related complications, which are the second leading cause of death among cancer survivors, as noted by global studies.

At the ACC.26 conference, GE HealthCare plans to showcase its comprehensive cardiology portfolio, including AI-enabled imaging technologies and advanced software solutions. These innovations support clinicians in diagnosing, treating, and monitoring cardiovascular diseases. The American Heart Association reports that cardiovascular disease is the leading cause of death in the U.S., emphasizing the need for efficient detection and treatment solutions, which GE HealthCare aims to provide.

GE HealthCare is experiencing positive growth, supported by a $21.8 billion backlog and strong enterprise deal momentum. The Pharmaceutical Diagnostics segment has grown by 12.7%, driven by demand for contrast media and PET imaging. However, the company faces challenges such as tariff impacts, margin pressures, and uneven performance across segments and regions.

Despite these challenges, GEHC's shares have increased by 0.2% over the past six months, contrasting with the industry's 20.4% decline and the S&P 500 Composite's 0.5% decrease. This resilience is reflected in the current stock price of $73.04, with a market capitalization of approximately $33.29 billion. The company's focus on innovation and strategic growth positions it well for future success.